Intech Investment Management LLC Acquires 33,542 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Intech Investment Management LLC boosted its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 147.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 56,305 shares of the biopharmaceutical company’s stock after purchasing an additional 33,542 shares during the period. Intech Investment Management LLC’s holdings in Halozyme Therapeutics were worth $3,223,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Boston Trust Walden Corp bought a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $23,211,000. CANADA LIFE ASSURANCE Co grew its stake in Halozyme Therapeutics by 29.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 130,856 shares of the biopharmaceutical company’s stock valued at $5,321,000 after purchasing an additional 29,845 shares in the last quarter. Swedbank AB acquired a new position in shares of Halozyme Therapeutics during the 1st quarter worth approximately $13,927,000. Creative Planning increased its position in shares of Halozyme Therapeutics by 43.2% during the 2nd quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock worth $1,953,000 after purchasing an additional 11,249 shares during the last quarter. Finally, Boston Partners raised its stake in shares of Halozyme Therapeutics by 14.1% during the 1st quarter. Boston Partners now owns 630,368 shares of the biopharmaceutical company’s stock worth $25,500,000 after purchasing an additional 77,976 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Halozyme Therapeutics

In other news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, September 18th. The stock was sold at an average price of $62.03, for a total transaction of $620,300.00. Following the completion of the sale, the senior vice president now owns 173,756 shares of the company’s stock, valued at approximately $10,778,084.68. This trade represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 60,000 shares of company stock worth $3,425,000 in the last ninety days. 2.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of recent analyst reports. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $58.00 to $62.00 in a report on Monday, October 7th. Benchmark restated a “buy” rating and set a $60.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $68.00 target price on shares of Halozyme Therapeutics in a research note on Wednesday. Cowen reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Finally, Piper Sandler raised their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a “neutral” rating in a research report on Monday, November 4th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $61.11.

Halozyme Therapeutics Trading Up 7.2 %

Shares of NASDAQ:HALO opened at $49.00 on Friday. Halozyme Therapeutics, Inc. has a 12-month low of $33.15 and a 12-month high of $65.53. The business has a 50 day moving average of $54.58 and a 200-day moving average of $53.48. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The stock has a market cap of $6.23 billion, a PE ratio of 16.23, a P/E/G ratio of 0.42 and a beta of 1.29.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.